Beinaglutide

Beinaglutide is a recombinant human GLP-1 receptor agonist consisting of the native human GLP-1(7-36) amide sequence produced through recombinant expression. The compound was developed by Shanghai Benemae Pharmaceutical (now part of Hua Dong Pharmaceutical, also called East China Pharmaceutical). It is one of few clinically approved GLP-1 agonists using the unmodified native human sequence rather than a modified analog.

The development positioning is distinctive. Most clinically used GLP-1 receptor agonists are modified to extend plasma half-life: Liraglutide and Semaglutide carry fatty acid modifications that bind albumin; Dulaglutide and Albiglutide are Fc-fused or HSA-fused; Exenatide is a Gila monster venom-derived analog with intrinsic resistance to DPP-4 cleavage; Lixisenatide is an exenatide-based analog. Native human GLP-1(7-36) has a plasma half-life of approximately 1 to 2 minutes due to rapid DPP-4 cleavage at the N-terminus. Beinaglutide's half-life is reported as approximately 11 minutes, suggesting some pharmaceutical formulation provides modest stability improvement over endogenous GLP-1.

The three-times-daily dosing schedule reflects this short half-life. From a clinical efficacy standpoint, the brief receptor engagement compared with the sustained engagement provided by long-acting analogs may explain the smaller weight-loss magnitudes reported in Beinaglutide trials versus modern long-acting GLP-1 agonists.

The Evidence

The compound has a Chinese Phase 3 evidence base supporting its NMPA approval:

Chinese Phase 3 in type 2 diabetes. Beinaglutide demonstrated HbA1c reduction in patients with type 2 diabetes inadequately controlled by metformin alone or combinations. Effect magnitudes documented were modest compared with longer-acting GLP-1 agonists, consistent with the shorter exposure profile.

Zhang et al., 2022. Phase 3 trial in obese Chinese patients reported weight reductions of approximately 5 to 8 kg over 24 weeks at maximum tolerated doses, supporting the obesity indication approval.

Approval scope. The NMPA approved Beinaglutide for obesity treatment in 2023 (the first GLP-1 agonist approved for obesity in China). The approval was based on Chinese Phase 3 trials rather than Western trial data. The compound is also approved for type 2 diabetes management.

Western literature recognition. Beinaglutide receives limited attention in Western diabetes and obesity literature, primarily because the three-times-daily dosing and inferior efficacy compared with semaglutide and tirzepatide limit its clinical relevance outside China.

Regulatory and Legal Status

China NMPA. Approved for obesity and type 2 diabetes.

FDA. No approval. No marketing authorization submission visible in public records.

EMA. No approval.

Compounding. Not on FDA bulk drug substances list. Not produced by US compounding pharmacies.

WADA. Not on 2026 Prohibited List.

Research-chemical availability. Some vendors offer Beinaglutide-labeled product. Identity verification is the buyer's responsibility.

Beinaglutide is the native human GLP-1(7-36) amide sequence. Its mechanism is identical to that of endogenous GLP-1.

GLP-1 receptor agonism. Beinaglutide binds the GLP-1 receptor (a class B G-protein-coupled receptor) on pancreatic beta cells, alpha cells, hypothalamic neurons, area postrema, and vagal afferents. Receptor activation triggers Gs-cAMP signaling and multiple downstream effects:

• Glucose-dependent insulin secretion from beta cells
• Suppression of glucagon release from alpha cells
• Slowed gastric emptying
• Reduced appetite through hypothalamic and brainstem signaling
• Reduced inflammation in vascular endothelium

The mechanism is identical to longer-acting GLP-1 agonists; the difference is pharmacokinetic rather than pharmacodynamic.

Pharmacokinetics. Native human GLP-1 has a plasma half-life of approximately 1 to 2 minutes due to rapid DPP-4 cleavage at the N-terminal His-Ala bond. Beinaglutide's recombinant production and formulation provide some extension to approximately 11 minutes, but the half-life is much shorter than fatty-acid-modified or Fc-fused analogs (hours to days). The three-times-daily dosing schedule before meals attempts to recapitulate physiological postprandial GLP-1 elevation, but plasma exposure remains intermittent rather than continuous.

Clinical consequence of short half-life. Pharmacological GLP-1 receptor engagement throughout the day (rather than only briefly post-prandially) supports the larger weight-loss effects observed with long-acting analogs. Beinaglutide's intermittent receptor engagement produces smaller cumulative effects on appetite and body weight compared with semaglutide's continuous receptor exposure.

Chinese clinical trial data in type 2 diabetes and obesity populations:

• HbA1c reduction of approximately 0.7 to 1.2 percent in T2D patients
• Body weight reduction of 5 to 8 kg over 24 weeks in obesity trials
• Improvement in fasting plasma glucose
• Modest reductions in systolic blood pressure
• Generally favorable tolerability with class-typical gastrointestinal side effects

The effect magnitudes for weight loss are notably smaller than those reported for semaglutide in the STEP program (approximately 15 percent body weight reduction over 68 weeks at 2.4 mg weekly) or tirzepatide in SURMOUNT trials (approximately 20 percent body weight reduction). The pharmacokinetic limitation is the most likely explanation.

Chinese approved dosing:

• Type 2 diabetes: Subcutaneous injection 0.1 mg three times daily before main meals, titrated to 0.2 mg three times daily based on tolerability and clinical response.
• Obesity: Similar dosing schedule with titration based on individual response.

The injection-before-meals schedule (5 to 15 minutes before main meals) attempts to match the natural physiological pattern of postprandial GLP-1 release.

Practical considerations. Three-times-daily injection is a substantial dosing burden compared with once-weekly semaglutide or tirzepatide. Adherence challenges in real-world use likely reduce the effectiveness gap between Beinaglutide and long-acting analogs further beyond the pharmacokinetic differences.

Research-chemical use sits outside the medical regulatory framework. Self-injection of unverified peptide product carries identity, purity, and dosing accuracy risks.

Adverse-event profile aligns with the GLP-1 class:

• Nausea (20 to 30 percent)
• Vomiting (5 to 10 percent)
• Diarrhea (10 to 15 percent)
• Constipation (5 to 8 percent)
• Injection site reactions
• Decreased appetite
• Modest tachycardia
• Rare cases of pancreatitis (class effect)
• Possible cholelithiasis (class effect with significant weight loss)

The intermittent pharmacokinetics may produce a different distribution of gastrointestinal symptoms compared with continuous-exposure long-acting agonists. Peak-and-trough plasma levels may concentrate nausea around peak post-injection levels rather than producing the persistent low-grade nausea sometimes reported with continuous-exposure agonists.

Class-effect considerations apply to Beinaglutide: rodent C-cell tumor findings (boxed warning relevance to humans uncertain), acute pancreatitis post-marketing reports, gallbladder events, diabetic retinopathy progression in subsets of patients.

Long-term safety beyond Chinese trial follow-up has not been characterized in Western-standard databases.

Beinaglutide is in the broader GLP-1 receptor agonist class. The clinical positioning differs substantially from Western-market alternatives due to the three-times-daily dosing burden:

• Semaglutide (once-weekly, larger weight-loss magnitudes, extensive Phase 3 evidence)
• Tirzepatide (once-weekly dual GIP/GLP-1 agonist, largest weight-loss effects in trials)
• Liraglutide (once-daily, original FDA-approved GLP-1 agonist for obesity)
• Dulaglutide (once-weekly Fc-fused)
• Exenatide (twice-daily or once-weekly extended-release)

In China, Beinaglutide competes with semaglutide and other imported GLP-1 agonists in the obesity market. The cost advantage of domestic production may favor Beinaglutide in Chinese clinical practice despite the dosing burden.

For users evaluating GLP-1 options outside China, Beinaglutide offers no efficacy or convenience advantage over the established options. Research-chemical Beinaglutide sourcing adds verification risk without practical clinical benefit.

External evidence-based comparators for obesity and type 2 diabetes include the full pharmaceutical-pipeline GLP-1 class plus established non-GLP-1 medications (metformin, SGLT2 inhibitors, etc.) and lifestyle interventions. Beinaglutide's niche is primarily Chinese market access through NMPA approval rather than clinical superiority on any specific metric.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.